Novartis gains ex-U.S. rights to Spark's gene therapy, and reports earnings

Novartis AG (NYSE:NVS; SIX:NOVN) gained ex-U.S. rights to develop and commercialize voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE). The pharma also reported its 4Q17 earnings on Wednesday.

Spark will receive $105 million up front and is eligible for $65 million in milestones, plus royalties in the mid 20s.

Read the full 470 word article

User Sign In